SOUTH SAN FRANCISCO, Calif. - IDEAYA Biosciences (NASDAQ:IDYA) announced today that topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in first-line HLA-A2-negative metastatic uveal melanoma will be delayed, according to a press release statement. The company's stock, currently trading at $32.75 with a market cap of $2.88 billion, has delivered a 78% return over the past year despite the clinical development uncertainties.
The company said the database lock is now projected for the first half of April, with topline data analysis to follow. The trial is testing darovasertib as a treatment for a specific subset of patients with metastatic uveal melanoma.
IDEAYA will host a live investor and analyst webcast following the data release. The webcast will feature company management and a guest key opinion leader. Pre-registration will be available through the company's investor relations website.
The company also announced its participation in two upcoming investor conferences. President and Chief Executive Officer Yujiro S. Hata will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on May 12, 2026. Hata will also participate in the Stifel 2026 Targeted Oncology Virtual Forum on May 19, 2026, hosted by Laura Prendergast.
Audio webcasts of both events will be available on IDEAYA's investor relations website, with replays accessible for 30 days following the live presentations.
IDEAYA focuses on developing targeted therapies for cancer through precision medicine approaches. The company's pipeline includes product candidates focused on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications. According to InvestingPro analysis, IDEAYA holds more cash than debt on its balance sheet and maintains a strong current ratio of 11.34, providing financial flexibility for its clinical programs. The platform's Fair Value analysis suggests the stock is currently undervalued, with an overall financial health score rated as "GOOD."
In other recent news, Ideaya Biosciences has made significant strides in its clinical trials and corporate development. The company has enrolled the first patient in its Phase 1 clinical trial of IDE892, a PRMT5 inhibitor targeting MTAP-deleted solid tumors, such as non-small cell lung cancer and pancreatic cancer. Additionally, Ideaya has initiated a Phase 1 trial for IDE034, a PTK7/B7H3 bispecific TOP1 antibody-drug conjugate, assessing its safety and tolerability.
In corporate developments, Ideaya appointed Dr. Theodora Ross as Chief Development Officer to lead early clinical development and contribute to the company's research and development strategy. This appointment comes as the company plans to advance its oncology pipeline. On the analyst front, Truist Securities reiterated a Buy rating with a $60 price target, highlighting the company's progress in its MTAP program. Similarly, Cantor Fitzgerald maintained an Overweight rating, noting anticipation for the Phase 2/3 trial readout expected in late March. These developments reflect the company's ongoing efforts in advancing its clinical trials and strengthening its leadership team.